前立腺肥大症の臨床

出版社: 医学図書出版
著者:
発行日: 2002-02-20
分野: 臨床医学:外科  >  泌尿器科学
電子書籍版: 2002-02-20 (第1版)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

5,390 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,695 円(税込)

商品紹介

この新しい本は、イラストを大いに取り入れた理解し易い初版の形式にならったが、その内容は広く最新のものである。将来の可能性を示唆するものばかりでなく、薬理学上の全ての最新の情報や新しいインターベンショナルな技術も含まれている。図はすべて最新のグラフィック技術を用いて描き直し、さらに多くの新しい画像を採用した。(「序文」より)

目次

  • 前立腺肥大症の臨床
    勝岡洋治・山本員久/訳
    《136ページ》

    ―目 次―

    第1章 緒言
    第2章 疫学と自然史
    第3章 解剖学、発生学、組織病理学
    第4章 内分泌学と病因論
    第5章 臨床的経過と評価
    第6章 外科的および内視鏡的治療
    第7章 インターベンショナル治療法の選択
    第8章 薬剤療法の選択
    第9章 将来展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 緒言

P.2 掲載の参考文献
Drummond ME McGuire A, Black N, Petticrew M, McPherson CK (1993) Economic burden of treated benign prostatic hyperplasia in the United Kingdom. British Journal of Urology, 71, 290-296.
Kirby RS (1994) Are the days of transurethral resection of the prostate for benign prostatic hyperplasia numbered? British Medical Journal, 309. 716-718.

第2章 疫学と自然史

P.6 掲載の参考文献
Andersen JT, Lehtoren J, Tvetev K and the Scandinavian BPH Study Group (1995) Can finasteride reverse the progress of BPH? A two year placebo-controlled study. Urology, 46, 631-637.
Araki H, Watanabe H, Mishima T, Nakao M (1983) High-risk group for benign prostatic hypertrophy. Prostate, 4, 253-264.
Arrighi HM, Guess HA, Metter EJ, Fozard JL (1990) Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate, 16, 253-261.
Ball AJ, Feneley RCL, Abrams PH (1981) The natural history of untreated 'prostatism'. British . Journal of Uroiogy, 53, 613-616.
Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. Journal of Urology, 132, 474-479.
Birkoff JD (1983) Natural history of benign prostatic hypertrophy. In : Benign Prostatic Hypertrophy, pp. 5-12. Edited by Hinman F and Boyarsky S. New York, Springer-Verlag.
Bourke JB, Griffin JP (1968) Diabetes mellitus in patients with prostatic hyperplasia. British Medical Journal, 4, 492-493.
Chute CC, Pauser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Leiber MM (1993) The prevalence of prostatism : apopulation-based survey of urinary symptoms. Journal of Urology, 150, 85-89.
Craigen AA, Hickling JB, Saunders CRG, Carpenter RG (1969) Natural history of prostatic obstruction. A prospective survey. Journal of the Royal College of General Practitioners, 18, 226-232.
Derbes VDR Leche SM, Hooker CW (1937) The incidence of benign prostatic hypertrophy among the whites and negroes in New Orleans. Journal of Urology, 38, 383-388.
Drach GW, Layton TN, Binard WJ (1979) Male peak urinary flow rate : relationship of volume voided and age. Journal of Urology, 122, 210-214.
Ekman P (1989) BPH epidemiology and ris k factors. Prostate, 2 (Suppl.), 23-31.
Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet, 338, 469-471.
Glynn RJ, Campion EW, Bouchard GR. Silbert JE (1985) The development of benign prostatic hyperplasia among volunteers in the normative ageing study. Journal of Epidemiology, 121, 78-81.
Gu FL, Xia TL, Kong XT (1994) Preliminary study of the frequency of benign prostatic hyperplasia and prostate cancer in China. Urology, 44, 688-691.
Kambal A (1977) Prostatic obstruction in Sudan. British Journal of Urology, 49, 139-141.
Moore RA (1943) Benign hypertrophy of the prostate. A morphological study. Journal of Urology, 50, 680-710.
Robson MC (1964) The incidence of benign prostatic hyperplasia and prostatic carcinoma in cirrhosis of the liver. Journal of Urology, 92, 307-310.
Ross RK, Bernstein L, Lobo RA, Shilnizu H, Stanezyk FZ, Pike MC (1992) 5alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339, 887-889.
Rotkin ID (1983) Origins, distribution, and risk of benign prostatic hypertrophy. In : Benign Prostatic Hypertrophy, pp. 10-21. Edited by Hinman F and Boyarsky S. New York, Springer-Verlag.

第3章 解剖学、発生学、組織病理学

P.13 掲載の参考文献
Blacklock NJ, Bouskill K (1977) The zonal anatomy of the prostate in man and the rhesus monkey (Macaca mulatta). Urological Research, 5, 163-167.
Gil Vernet S (1953) Patalogia Urogenital : Biologia y Patologia de la Prostata, Vol 1, Book 2, pp. 1-72. Madrid, Editorial Paz Montalvo.
Lowsley OS (1930) Embryology, anatomy and surgery of the prostate gland with report of operative results. American Journal of Surgery, 8, 526-541.
McNeal JE (1968) Regional morphology and pathology of the prostate. American Journal of Clinical Pathology, 49, 347-357.
McNeal JE (1978) Origin and evolution of benign prostatic hyperplasia. Investigative Urology, 15, 340-345.
McNeal JE (1983) The prostate gland : morphology and pathobiology. Monographs in Urology, 9, 3-33.
Reese JH, McNeal JE, Redwine EA, Samloff, Stamey TA (1986) Differential distribution of pepsinogen II between the lobes of the human prostate and the seminal vesicle. Journal of Urology, 136, 1148-1152.
Reese JH, McNeal JE, Redwine EA, Samloff, Stamey TA (1988) Tissue type plasminogen activator as a marker for functional zones within the human prostate gland. Prostate, 12, 47-53.
Weiss MA, Mills SE (1988) Atlas of Genitourinary Tract Disorders, pp. 13.1-13.12. New York, Gower Medical Publishing.
P.14 掲載の参考文献
1) Barry, MJ. : Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clic. North Am, 17 : 495-507, 1990
2) Glynn, R. J., Campion, E. W., Bouchard, G. R., et al : The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am. J. EpidemioL, 121 : 78-90, 1985
3) 熊本悦明, 塚本泰司 : 前立腺肥大症の疫学. CURRENT THERAPY., 8 : 1612-1616, 1990
4) 厚生省編厚生白書平成8年版. 8-11
5) 淡路健雄, 堀江公仁子, 辻本豪三 : α-アドレナリン受容体 : 遺伝子とシグナル伝達機構 : α. 交感神経受容体の分子治療学-遺伝子から機能へ-. 編著 : 辻本豪三, メディカルレビュー社. (東京), 19-27
6) Moriyama, N., Kurimoto, S., Horie, S., et al : Detection ofαt-adrenoceptor subtype in human hypertrophied prostate by in situ hybridization. Histochem. J., 28 : 283-288, 1996
7) Nasu, K., Moriyama, N., Kawabe, K., et al : Quantification and distribution ofαi-adrenoceptor subtype mRNAs in human prostate : comparison of benign hypertrophied tissue and nonhypertrophied tissue. Br. J. PharmacoL, 119 : 797-803, 1996
8) Walden, P. D., Gerardi. C., Lepor, H. : Localization and expression of the α1a-1, α1B and α1D adrenoceptors in hyperplastic and non-hyperplastic human prostate. J. Urol., 161 : 635-640, 1999
9) Forray, C., Bard, J. A., Wetzel J. M., et al : The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1C subtype. Mol. PharmacoL, 45 : 703-708, 1994
10) Shibata, K., Foglar, R., Horie, K., et al : KMD-3213, a nover, potent, α1a-adrenoceptor-selective antagnist : Characterization using recombinant human α1-adreonoceprors and native tissues. Mol. Pharmacol., 48 : 250-258, 1995
11) 山口脩, 深谷保男, 白岩康夫, 他 : 前立腺肥大症に伴う排尿障害に対するナフトピジル (KT-611) の用量反応性および臨床的有用性の検討-プラセボ対照二重盲検比較試験-. 基礎と臨床, 31 : 1315-1360, 1997
12) Malloy, B. J., Price, D. T., Price, R. R., et al : α1-adrenergic receptor subtypes in human detrusor. J Urol., 160 : 937-943, 1998
13) Hampel, C., Dolber, P. C., Savic, S. L., et al : Changes in α1 adrenargic receptor (AR) subtype gene expression during bladder outlet obstruction of rats. J. UroL, 163 : 228, 2000
14) Cavalli, A., Lattion, A. L, Hummler, E, et al : Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc. NatL Acad. Sci., 94 : 11589-11594, 1997
15) Takei, R., Ikegaki, L, Shibata, K., et al : Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn. J. PharmacoL, 79 : 447-454, 1999
16) 北濱勝弘, 横田耕一, 洲加本孝幸, 他 : 新規α1アドレナリン受容体遮断薬, ナフトピジルの摘出血管収縮および起立性低血圧反射に対する作用. 薬理と治療, 27 : 75-85, 1999
17) 河邉香月 : α-プロッカー. 臨床泌尿器科, 46 : 295-301, 1992
18) 河邉香月, 上野精, 滝本至得, 他 : 前立腺肥大症に伴う排尿障害に対するYM617の臨床評価-プラセボを対照とした多施設共同二重盲検比較試験-. 泌尿器外科, 4 : 231-242, 1991
19) 河邉香月, 土田正義, 島崎淳, 他 : 前立腺肥大症に伴う排尿障害に対するウラピジルの治療効果-二重盲検比較試験による検討-. 泌尿器外科, 5 : 735-745, 1992
20) 熊本説明, 塚本泰司, 八竹直, 他 : 前立腺肥大症に伴う排尿障害に対する塩酸テラゾシンの臨床評価 (II) -プラセボを対照薬とした二重盲検比較試験-. 泌尿器外科, 5 : 823-840, 1992
21) 大岡均至, 堅田明浩, 原口貴裕, 他 ; 前立腺肥大症に伴う排尿障害に対するナフトピジルの臨床的有用性の検討. 日本神経因性膀胱学会, 11 : 75, 2000
22) 三宅修, 高原史郎, 吉村一宏, 他 : 前立腺肥大症に対する薬物治療-ナフトピジル初期50mg投与の評価-. 泌尿器外科, 14 : 363-371, 2001
23) Yamada, S. Suzuki, M., Tanaka, C., et al : Comparative study on α1-adrenoceptor antagonist binding in human prostate and aorta. Clin. Exp. Phamacol. Physiol., 21 : 405-411, 1994
24) Okada, H., Kamidono, S., Yoshioka, A., et al : A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. Br. J. Urol. Int., 85 : 676-681, 2000
25) Tsuji, T. : Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia : A short-term open, randomized multicenter study. Int J. Urol., 7 : 199-205, 2000
26) 杉山高秀, 大西規夫, 宮武竜一郎, 他 : 塩酸タムスロシン (ハルナール(R)) の有用性と適応の可能性. 排尿障害プラクティス, 8 : 161-164, 2000
27) Testa, R., Taddei, C., Poggesi, E., et al : REC 15/2739 (SB216469) : A novel selective α1 adrenoceptor antagonist. Pharmacol. Comm., 6 : 79-86, 1995
28). 森田隆, 近藤俊 : ヒト前立腺肥大症腺腫のα受容体に対する各種のα1 blockerの効果の比較検討. 日本泌尿器科学会誌, 83 : 334-337, 1992
29) 朴英哲, 栗夛孝, 並木幹夫, 他 : 前立腺肥大症に伴う排尿障害に対するウラピジル (エブランチル(R)) の長期使用に関する多施設共同研究. 泌尿器外科, 13 : 1519-1531, 2000
30) 安田耕作, 山西友典, 島崎淳, 他 : ウラピジル (BKU) の神経因性膀胱に伴う排尿障害に対するプラセボを対照とした : 重盲検比較試験. 日本神経因性膀胱学会誌, 7 : 3-24, 1996
31) 鈴木英訓, 大西哲郎, 池本庸, 他 : 前立腺肥大症における塩酸テラゾシン (ハイトラシン) の臨床研究-1日1回投与と1日2回投与の比較. 泌尿器外科, 13 : 606, 2000
32) 玉置雅弘, 上田朋宏, 影山進 : 塩酸テラゾシン単独投与による前立腺肥大症患者の血清脂質の変動について. 泌尿器科紀要, 45 : 827-830, 1999
33) 山口脩, 白岩康夫, 小林正人, 他 : 前立腺肥大症に伴う排尿障害に対する塩酸プラゾシン錠 (ミニプレス(R)) の臨床評価-多施設共同によるパラプロストカプセルとの二重盲検比較試験-. 医学と薬学, 19 : 411-429, 1988
34) 南祐三, 酒井英樹, 金武洋, 他 : 前立腺肥大症に対する酢酸クロルマジノン長期投与の臨床効果-25mg/li維持療法の検討-. 西日本泌尿器科, 55 : 575-581, 1993
35) 千葉裕, 折笠精一 : 前立腺肥大症に対する抗アンドロゲン療法の適応と投与法-前立腺自然史と薬剤間欠療法-. Prog. Med., 19 : 2363-2367, 1999
36) Marberger. M. J. : Long-term effects of finasteride in patients with benign prostatic hyperplasia : a double-blind, placebo-controlled, multicenter study. Uro., 51 : 677-686, 1998
37) Hagerty, J. A., Ginsberg. P. C, Harmon, J. D., et al : Pretreatment with finasteride decreases perioperative bleeding associated with transurethal resection of the prostate. Uro., 55 : 684-689, 2000
38) Donohue, JF, Sharma, H., Natalwala, S., et al : Finasteride given for 2 weeks pre-operatively reduces bleeding in patioents undergoing TURP. J. Uro., 165 : 200, 2001
39) 志田圭三 : アンチアンドロゲンに関する基礎的, 臨床的研究-前湖泉腫瘍 (肥大と癌) のアンドロゲン依存性とアンチアンドロゲン剤の応用-. ホルモンと臨床, 28 : 899-928, 1980
40) 山中英寿, 古作望, 牧野武雄, 他 : アリルエストレノールの抗前湖泉作用に関する基礎的, 臨床的研究. 泌尿器科紀要, 29 : 1133-1145, 1983
41) 志田圭三, 小柳知彦, 川倉宏', 他 : 重盲検法におけるアリルエストレノールの前立腺肥大症に対する臨床効果. 泌尿器科紀要, 32 : 625-648, 1986
42) 熊本悦明, 山口康宏, 佐藤嘉一, 他 : Anti-androgenの性機能に及ぼす影響-アリルエストレノールおよび酢酸クロルマジノンの重盲検法比較試験 第1報: 夜間睡眠時勃起現象 (NPT) 測定による検討-. 泌尿器科紀要, 36 : 213-226, 1990
43) 熊本悦明, 山口康宏, 佐藤嘉一, 他 : Anti-androgenの性機能に及ぼす影響-アリルエストレノールおよび酢酸クロルマジノンの二重盲検法比較試験 第II報 : 自記式質問紙法による検討-. 泌尿器科紀要, 36 : 227-244, 1990
44) 小杉道夫, 堀永実, 池内幸一 : 前湖泉肥大症に対するallylestrenol (Perselin) 投与前後のPSA, テストステロン値変動についての検討. 泌尿器外科, 13 : 836, 2000
45) 野口和美, 上村博司, 武田光正, 他 : 前立腺肥大症に対するアンチアンドロゲン剤の投与および中断によるPSA値の変化. 泌尿器科紀要, 46 : 605-607, 2000
46) 伊藤善一, 黒沢功, 山中英寿, 他 : 酢酸クロルマジノンのアンチアンドロゲン作用 特にその作用機序解明に関する研究. 日本泌尿器科雑誌, 68 : 537-552, 1977
47) Murakoshi, M, Tagawa, M., Ikeda, R., et al : Immunologicalization of androgen receptor (AR) and steroid 5 alpha-reductase typeII (5 alpha-reductase type II) in canine prostate. Effect of antiandrogen, chlormadinone acetate (CMA)-. Acta. Histochem. Cytochem., 33 : 223-229, 2000
48) Murakoshi, M., Tagawa, M., Ikeda, R, et al : Atrophic effects of antiandrogen, chlormadinone acetate (CMA) on dog prostate with spontaneous benign prostatic hyperplasia. J. Toxicol. Sci., 25 : 143-150, 2000
49) 志田圭三, 小柳知彦, 熊本悦明, 他 : 前立腺肥大症に対するTZP-61の臨床効果-プロスタール錠25を対照とした二重盲検試験-. 臨床医薬, 4 : 1145-1164, 1988
50) 上木修, 川口光平, 勝見哲郎, 他 : α1ブロッカー単独療法無効前立腺肥大症患者に対する酢酸クロルマジノン徐放錠併用による臨床効果と前立腺縮小効果. 泌尿器科紀要, 44 : 565-573, 1998
51) 阿曽佳郎, 本間之夫, 熊本悦明, 他 : 5α-reductase阻害剤MK-906の前立腺肥大症に対する臨床第III相試験-酢酸クロルマジノン徐放錠を対照薬とする運盲検群間比較試験-. 泌尿器外科, 8 : 237-256, 1995
52) 前立腺肥大症診療マニュアル編集 : 財団法人 前立腺研究財団, 250-256, 金原出版
53) 中野博, 広本宣彦, 仁平寛巳, 他 : 前立腺肥大症に対するeviprostatの臨床効果について (二重盲検法). 泌尿器科紀要, 21 : 433-452, 1975
54) 佐々木進, 前川正信, 岸本武利, 他 : 前立腺肥大症に対するeviprostatの臨床効果-二重盲検法による検討-. 西日本泌尿器科, 37 : 647-660, 1975
55) 前立腺肥大症診療マニュアル編集 : 財団法人 前立腺研究財団, 257-264, 金原出版
56) 勝岡洋治, 鈴木俊明 : 前立腺肥大症における経尿道的高温度治療α1ブロッカー投与との比較. 新医療, 9月号113-116, 2000
57) 排尿障害臨床試験ガイドライン作成委員会 (編) : 排尿障害臨床試験ガイドライン. 医学図書出版

第4章 内分泌学と病因論

P.23 掲載の参考文献
Anderson KM, Liao S (1968) Selective retention of dihydro-stestosterone by prostatic nuclei. Nature, 219, 277-279.
Barrack ER, Bujnovsky P, Walsh PC (1983) Subcellular distribution of androgen receptors in human normal, benign hyperplastic and malignant prostatic tissue : characterization of nuclear salt-resistant receptors. Cancer Research, 43, 1107-1116.
Barrack ER, Barry SJ (1987) DNA synthesis in the canine prostate : effects of androgens and oestrogen treatment. Prostate, 10, 45-56.
Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. Journal of Biological Chemistry, 243, 2012-2021.
Coffey DS (1986) The endocrine control of normal and abnormal growth of the prostate. In : Urologic Endocrinology, pp. 170-193. Philadelphia, WB Saunders.
Cunha GR (1972a) Tissue interactions between epithelium and mesenchyme of urogenital and integumental origin. Anatomical Record, 172, 529-542.
Cunha GR (1972b) Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anatomical Record, 172, 179-196.
Davies P, Eaton CL (1989) Binding of epidermal growth factor by normal, hypertrophic and carcinomatous prostate. Prostate, 14, 123-132.
Franks LM, Barton AA (1960) The effects of testosterone on the ultrastructure of the mouse prostate in vivo and in organ culture. Experitnental Cell Research, 19, 35-50.
Griffiths K, Davies P, Eaton CL, Harper ME, Turkes A, Peeling WB (1991). In : Endocrine Dependent Tumours, pp. 83-130. Edited by Vbig KB and Knabbe C New York, Raven Press.
Imperato-McGinley J, Guevro L, Gauteri T, Petersen RE (1974) Steroid 5-alpha-reductase deficiency in a man : an inherited form of pseudohermaphroditism. Science, 186, 1213-1215.
Isaacs JT (1987) Control of cell proliferation and cell death in the normal and neoplastic prostate. A stem cell model. In : Benign Prostatic Hyperplasia, Vol. 2 (NIH Publication 87-2881). pp. 85-94. Edited by Rogers CH, Coffey DS. Cunha G, et al. Washington DC, US Dept of Health and Human Services.
Martikainen R Kyprianou N, Isaacs JN (1990) Effect of transforming growth factor-beta on proliferation and cell deaths of rat prostatic cells. Endocrinology, 127, 2963-2968.
Mori H, Maki M, Oishi K, Jaye M, Igarashi K, Yoshida O (1990) Increased expression of genes for basic fibroblast growth factor and transforming growth t'actor type b, in human benign prostatic hyperplasia. Prostate, 16, 71-80.
Siiteri PK, Wilson JD (1970) Dihydrotestosterone metab olism in prostate hypertrophy. I. The formation of content of dihydrotestosterone in the hypertrophic prostate of man. Journal of Clinical Investigation, 49, 1737-1745.
Trachenberg J, Hicks LL, Walsh PC (1980) Androgen and estrogen receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. Journal of Clinical Investigation, 65, 1051-1059.
Vermeulen A (1973) The Endocrine Function of the Human Testis, Vol. 1, p. 157. New York, Academic Pres : .
Walsh PC, Hutchins GM, Ewing LL (1983) Tissue content of dihydrotestosterone in human prostate hyperplasia is not supranormal. Journal of Clinical Investigation, 72., 1772-1777.

第5章 臨床的経過と評価

P.41 掲載の参考文献
Abrams PH, Griffiths DJ (1979) The assessment of prostatic obstruction from urodynamic measurements and from residllal urine. British Journal of Urology, 51, 129-134.
Allhoff E, Riese W, Eifingen M, Pcthke J, Jonas U (1989) Prostate specific antigen-comparative clinical appreciation of aserodiagnostic measure after 8 years ofexperience. World Journal of Urology, 7, 12-16.
Arrighi HM, Guess HA, Mener EJ, Fozard JL (1990) Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate, 16, 253-261.
Barry MJ, Fowler FJ. O'Leary MR Bruskevitz RC, Holtgrewe HL. Mebust WK (1992) The American Urological Association symptom index for benign prostatic hyperplasia. Journal of Urology, 148, 1549-1557.
Benson MC. Whang IS, Pantuck A, Ring K, Kaplan SA. Cooner WH (1992) The use of prostate specific antigen density : a means of distinguishing benign prostatic hypertrophy and prostate cancer. Journal of Urology, 147, 815-818.
Boyarsky S, Jones G Paulson DF, Front CR (1977) A new look at bladder neck obstruction by the Food and Drug Administration regulators : Guidelines for investigation of benign prostatic hypertrophy. Trans American Assaociation of Genito-Urinary Surgeons, 68, 29-32.
Brading AE Turner WH (1994) The unstable bladder : towards a common mechanism. British Journal of Urology, 73, 3-8.
Bruskevitch RC, Iversen R Madsen PO (1982) Value of postvoid residual urine determination in evaluation of prostatism. Urology, 20, 602-604.
Carter HB, Pearson JD. Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate specific antigen Ievels in men with and without prostate disease. Journal of the American Medical Association, 270, 860.
Catalona WJ. Smith DS, Ratliff DL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole JA (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine, 324 (17), 1156-1161.
Ellis WJ, Gramburn EAG, Chen GL, Preston SD, Brawer MK (1993) The inability of prostate specific antigen density to enhance the predictive value of PSA in the diagnosis of prostate cancer. Journal of Urology, 149, 415A.
George NJR, Slade N (1979) Hesitancy and poor stream in neurologically normal younger men without outflow obstruction. 」British Journal of Urology, 51, 506-510.
Gerstenberg TC, Andersen JT, Klarskov P, Ramirez D, Hald T (1982) High flow intravesical obstruction in men : symptomatology, urodynamics and thc results of surgery. Journal of Urology, 127, 943-945.
Gilpin SA, Gosling JA, Barnard RJ (1985) Morphological and morphometric studies of the human obstructed, trabeculated urinary bladder. British Journal of Urology, 57, 525-529.
Gilpin SA, Gilpin CJ, Dixon JS, Gosling JA, Kirby RS (1986) The effect of age on the autonomic innervation of the bladder. British Journal of Urology, 58, 378-381.
Griffiths D, Van Mastrigt R, Bosch R (1989) Quantification of urethral resistance and bladder function during voiding. Neurology and Urodynamics, 8, 17-27.
Guess HA, Heyse JF, Gormley GJ (1993) The effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate, 22, 31-37.
Hricak H, Jeffrey RB, Dooms CG, Tanagho EA (1987) Evaluation of prostatic size. A comparison of ultrasound and magnetic resonance imaging. Urological Radiology, 9, 1.
Jensen KE, Bruskevitch RC, Iversen P, Madsen PO (1983) Predictive value of voiding Pressures in benign prostatic hyperplasia. Neurology and Urodynamics, 2, 117-125.
Jorgensen JB, Jensen KME, Bille-Brahe E, Morgensen P (1986) Urofiowmetry in asymptomatic elderly males. British Journal of Urology, 58, 390-393.
Kirby RS, Fowler CJ, Gosling JA, Milroy EJG, Turner-Warwick RT (1986) Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 49, 554-562.
Madsen PO, Iversen PA (1983) A point system for selecting operative candidates. In : Benign Prostatic Hypertrophy, pp. 763-769. Edited by Hinman F Jr and Boyarsky S. New York, Springer-Verlag.
Mebust WK, Holtgrewe HL, Cockett ATK (1989) Transurethral prostatectomy : immediate and postoperative complications : a cooperative study of 13 participating institutions evaluating 3885 patients. Journal of Urology, 141, 243-247.
Oesterling JE, Jacobsen SJ. Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum prostate specific antigen in a community based population of healthy men. Establishment of age-specific reference ranges. Journal of the American Medical Association, 270, 860-864.
Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenmen UH, Dowell B, Lovgren T, Liza H (1995) Free, complexed and total serum prostate specific antigen : the establishment of appropriate reference ranges for their concentrations and ratios. Journal of Urology, 154, 1090-1095.
Sacks S, Aparico SAJR, Bevan A (1989) Late renal failure due to prostatic obstruction : a preventable disease. British Medical Journal, 298, 156-157.
Schaefer W (1985) Urethral resistance. Urodynamic concepts of physiological and pathological bladder outlet function during voiding. Neurology and Urodynamics, 4, 161-201.
Siroky MB, Olsson CA, Krane RJ (1980) The flow rate nomogram I : Development. Journal of Urology, 123, 208-210.
Speakman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosling JA (1987) Bladder outflow obstruction-cause of denervation supersensitivity. Journal of Urology, 138, 1461-1467.
Stenman UH, Leinoren J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate specific antigen and alpha 1-antichymotrypsin is the major form of prostate specific antigen in the serum of patients with prostatic cancer : assay of the complex improves clinical sensitivity for cancer. Cancer Research, 51. 222.

第6章 外科的および内視鏡的治療

P.58 掲載の参考文献
Abrams PH (1978) Urodynamic changes following prostatectomy. Urologia Internationalis, 33, 181-186.
Blandy JP (1978) The indications for prostatectomy. Urologia Internationalis, 33, 159-170.
Bruskevitz RC. Larsen EH, Madson PO (1986) 3 year follow-up of urinary symptoms after trans-urethral resection of the prostate. Journal of Urology, 136, 613-615.
Chilton CP, Morgan RJ, England HR, Blandy JP (1978) A critical evaluation of the results of trans-urethral resection of the prostate. British Journal of Urology, 50, 542-546.
Creevy CD. Webb EA (1947) A fatal haeniolytic reaction following tralls-urethral resection of the pros tate gland. Surgery, 21, 56-66.
Emberton M, Neal DE, Black M. Fordham M. Harrison M. McBrien MP. WiHiams RE. McPherson K, Devlin HB (1996) The effectiveness of prostatectomy on symptom severity and quality of life. British Journal of Urology, 77, 233-247.
Freyer JP (1902) Structure of the Urethra and Hypertrophy of the Prostate, 2nd ed. Paris, Bailliere. Tindall. Cox.
Hargreave TB. Stephens on TP (1977) Potency and prostatectomy. British Journal of Urology, 49, 683-688.
Holtgrewe HL. Valk WL (1962) Factors intluencing mortality and morbidity of trans-urethral prostatectomy : a study of 2013. Journal of Urology, 87, 450-459.
Holtgrewe HL, Mebust WK, Dowd JB (1989) Trans-urethral prostatectomy : practise aspects of the dominant operation in American urology. Journal of Urology, 141, 248-253.
Lentz MC, Mebust WK. Foret JD, Melchior J (1977) Urethral strictures following trans-urethral prostatectomy-a review of 223 resections. Journal of Urology, 117, 194-196.
Mebust WK. Holtgrewe HL, Cockett ATK (1989) Transurethral prostatectomy : immediate and post-operative complications : a cooperative study of 13 participating institutions evaluating 3885 patients. Journal of Urology, 141, 243-247.
Milroy EJG. Chapple CR. Eldin A (1990) A new treatment for urethral strictures-a permanently implanted metal stent. Journal of Urology, 141, 1420-1422.
Murphy LJT (1972) History of Urology, p. 428. Springfield, Illinois, Charles C Thomas.
Neal DE. Ranisden PD. Sharples L. Smith A, Powell PH. Styles RA (1989) Outcome of prostatectomy. British Medical Journal, 299, 762-767.
Orandi A (1987) Trans-urethral incision of the prostate compared with transurethral resection of the prostate in 132 matching cases. Journal of Urology, 138, 810-815.
Riehmann M. Kncs JM, Heisev D. Madsen PO. Bruskevitz RC (1995) Transurethral resection versus incision of the prostate : a randomised prospective stu dy. Urology, 45, 768-775.
Roos NP. Wennberg JE. Malenka DJ. Fisher ES. McPherson K, Anderson TF (1987) Mortality and re-operation after open and trans-urethral resection of the prostate for benign prostatic syperplasia. New England Journal of Medicine, 320, 1120-1124.
Wasson JH. Reda DJ. Bruskevitz RC, Elinson J. Keller AM. Henderson WG (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. New England Journal of Medicine, 332, 79.
Webster G. Kirby RS. King L. Goldwasser B (eds) (1993) Reconstructive Urology, pp. 657-730. Oxford : Blackwell Scientific Publications.
Wennberg JE. Roos N. Sola L (1987) Use of claims data systems to evaluate health care outcomes mortality and reoperationn following prostatectomy. Journal of the American Medical Association, 257, 933-936.
Wishnow KI. Newman CT, Cromeens DE, Price RE, Eschenbach AC (1990) Safety of trans-urethral laser treatment of the prostate. Journal of Urology, 145, 267A.
Young HH, (1913) A new procedurc (punch operation) for small prostatic bars and contracture of the prostatic orifice. Journal of the American Medical Association, 60, 253-257.

第7章 インターベンショナル治療法の選択

P.89 掲載の参考文献
Aalkjaer V (1962) Trans-urethral resection versus dilatation treatment in hypertrophy of the prostate : a comparison of the effects of the methods. Urologia Internationalis, 14, 119-124.
Abbou CC, Payan C, Viens-Bitker C, Richard F Boccon-Gibot L Jardin A. Beurton D, Le DucA. Fermanian J, Thibault P and the French Hyperthermia Group d 995) Transrectal and transurethral hyperthermia versus : ham treatment in benign prostatic hypcrplasia : a double-blind, randomized, multicenfre clinical trial. British Journal of Urology, 76, 619-624.
Anson A, Nawrocki J. Buckley J, Fowler C. Kirby RS, Laurence W, Paterson P. Watson G (1995) A multicentre, randomised, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology, 46, 305-310.
Astrahan MA, Sapozink MD, Cohen D, Luxton GL, Kampp TD, Boyd S, Petrovich Z (1989) Microwave applicator for trans-urethral hyperthermia of benign prostatic hyperplasia. International Journal of Hyperthermia, 5, 283-286.
Baert L, Ameye E Willemen R Vandenhove J, Lauweryns J, Astrahan M, Petrovich Z (1990) Trans-urethral microwave hyperthermia for bcnign prostatic hypcrplasia : preliminary clinical and pathological resuhs. Journal of Urology,144, 1383-1387.
Bihrle R, Foster RS, Regand J, Kopecky K, Hawes R, Fry FJ, Donahue JP (1991) Noninvasive Ultrasound Produced Volume Lesion in the Prostate. 22nd congress of the Socete Internationale d'Urologie. Abstracts Book, p. 433.
Bihrle R, Foster RS, Sangvi NT, Donaghue JR Hood PJ (1994) High intensity focused ultrasound for the treatment of benign prostatic hyperplasia : early United States clinical experience. Journal of Urology, 151, 1271-1275.
Birkhoff JD (1983) In : Benign Prostatic Hypertrophy, pp. 5-21. Edited by Hinman F and Boyarsky S. New York, Springer-Verlag.
Burhenne HJ, Chisholm RJ, Quenville NF (1987) Prostatic hyperplasia ; radiological intervention. Radiology, 152, 655-657.
Carter St C. Patel A. Reddy R Ramsay J (1991) Single session transurethral microwave thermotherapy for the treatment of benign prostatic obstruction. Journal of Endocrinology, 5, 137-144.
Castenada E Reddy R Wass ermann N, Hulbert J, Lund G, Letourneau J. Hunter DW. Castenada-Zuniga WR, Amplatz K (1987) Benign prostatic hypertrophy : retrograde dilatation of the prostatic urethra in humans. Radiology, 163, 644-653.
Chapple CR, Christmas TJ, Milroy EJG (1990a) A twelve week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urologia Internationalis, 45, 47-55.
Chapple CR. Milroy EJG. Rickards D (1990b) permanently implanted urethral stent for prostatic obstruction in the unfit patient. British Journal of Urology, 66, 58-65.
Cook SP, Renz EA, Barrack RL, Thomas KA, Harding AF, Haddad RJ, Milieic M (1985) Clinical and metallurgical analysis of retrieved internal fixation devices. Clinical Orthopaedics, 194, 236-247.
Costello AJ, Shaffer BS (1993) Laser ablation of benign prostatic hyperplasia (BPH) : two and a half year experience with right angle delivery systems, Journal of Urology, 149, 215A.
Cowles RS. Kabalin JN. Childs S, Lepor H, Dixon C, Stein B, Zabbo A (1995) A prospective, randomised comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology, 46, 155-160.
Devonec M, Cathaud M, Carter S, Berger N, Perrin P (1990) Trans-urethral microwave application : temperature sensation and thermokinetics of the human prostate. Journal of Urology, 143, 414A.
Devonec MA, Berge N, Perrin O (1991) Trang. urethral microwave heating of the prostate-or from hyperthermia to thermotherapy. Journal of Endourology, 5, 129-135.
De Wldt MJAM, De La Rosette JDCM (1995) Transurethral microwave thermotherapy : an evolving technology in the treatment of benign prostatic enlargement. British Journal of Urology, 76, 531-538.
Diesting W (1956) Trans-urethral dilatation of the prostate : a new method in the treatment of hypertrophy. Urologia Internationalis, 2, 158-171.
Fabian KM (1980) Der intraprostatische "partielle Katheter" (urologische spirale). Urologe A, 23, 229-233.
Franck (1938) Die sprengung des prostataringes. Munch Med Wochenschr, 85, 777-782.
Fuselier HA. Roth RA, Babayan RK, McCullough, Cordon JO, Reese JH, Crawlbrd ED, Smith JA. Murchison RJ, Kaye KW (1993) TULIP-National Human Coopcrative Study results. Journal of Urology, 149, 215A.
Gill KP, Machan LS, Allison DJ, Wiuiams G (1989) Bladder outtlow obstruction aiid urinary retention from prostatic hypertrophy treated by balloon dilatation. British Journal of Urology, 64, 618-622.
Giovanella BC, Stehlin JS, Morgan AC (1976) Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Research, 36, 3944-3962.
Gonder MJ, Soancs WA, Shulman S (1966) Cryosurgical treatment of the prostate. Investigative Urology, 3, 372-378.
Green NA (1977) Cryosurgery of the prostate gland. Annals of the Royal College of Surgeons of England, 59, 288-297.
Haar G. Rivens I, Chen L, Riddler S (1991) High intensity focused ultrasound for the treatment ot rat tumours. Physical Medicine Biology, 36, 1495-1502.
Harrison NW, De Souza JV (1990) Prostatic stenting for outflow obstruction. British Journal of Urology, 65, 192-196.
Hollingsworth E (1910) Dilatation of the prostatic urethra for the relief of symptoms of prostatic enlargement. Annals of Surgery, 51, 597-599.
Holmes S, Kirby RS (1992) Encrustation occurring on an intra-prostatic spiral-a case report. British Journal of Urology, 69, 322-323.
Kabalin (1993) Laser prostatectomy performed with a right angle firing neodymium : YAG fiber at 40 watts power setting. Journal of Urology, 150, 95-99.
Kirby RS, Heard S, Miller P, Eardley I, Holmes S. Christmas TJ. Vale J. Bryan J, Liu S (1992) The use of the ASI titanium stent in the management of bladder outflow obstruction due to BPH. Journal of Urology, 148, 1195-1197.
Kirby RS, Williams G, Witherow R, Milroy EJG, Philp T (1993) The Prostatron transui-ethral rnicrowave device in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia. British Journal of Urology, 72, 190-194.
Lee F, Bahn DK, McHugh TA, Omik GM, Lee FT (1994) US-guided percutaneous cryoablation of the prostate. Radiology, 192, 769-776.
Lepor H, Sypherd R, Denis J, Machi G (1991) A randomized double-blind study colllparing the efficacy of cystoscopy versus balloon dilatation of the prostate in males with symptomatic benign prostatic hyperplasia. Journal of Urology, 145, 362A.
Lindner A, Golomb J, Siegel Y, Lev A (1987) Local hyperthermia of the prostate gland for the treatment of benign prostatic hypertrophy and urinary retention. British Journal of Urology, 60, 567-571.
Lindner A, Siegel YI, Korczak D (1990a) Serum prostate specific antigen levels during hyperplasia. Journal of Urology, 144, 1388-1389.
Lindner A, Siegel YI, Saranga R. Korczak D. Matznin H, Braf Z (1990b) Comprications in hyperthermia treatment of benign prostatic hyperplasia. Journal of Urology, 144, 1390-1392.
McLoughlin J, Keanc DF, Jager R, Gill KP, Machann L, Williams G (1991) Dilatation of the prostate with a 35 mm balloon. British Journal of Urology, 67, 177-181.
McNicholas TA, Steger AC, Brown SG (1993) Interstitial laser coagulation of the prostate. An experimental study. British Journal of Urology, 71, 439-444.
Miller PD, Parsons K, Ramsav EW (1995) Transurethral microwave thermoablation (TUMT) for benign prostatic hyperplasia using a new device. Journal of Urology, 153, 532A.
Milroy EJG, Chapple CR, Eldin A (1990) A new treatment for urethral strictures-a permanently implanted urethral stent. Journal of Urology, 141, 1120-1122.
Nielson KK, Klarsov P, Nordling J. Andersen JF. Holm HH (1990) The intra-prostatic spiral. New treatment for urinary retention. British Journal of Urology, 65, 500-503.
Ogden EW, Reddy P. Johnson H, Ramsay JWA, Carter STC (1993) Sham versus transurethral microwave therapy in patients with benign prostatic bladder outflow obstruction. Lancet, 341, 14-17.
Parker C, Birch B, Gehster J, Miller R (1989) Use of stents for treating obstruction of urinary flow. British Medical Journal, 299, 120.
Perlmutter Ap, Muschter R, Razvi HA (1995) Electrosurgical vaporization ofthe prostate in the canine model. Urology, 46, 518-523.
Quinn SF, Dyer R, Samthers R, Glass T, wright E, Roberts C, Burke J, Argenbright RT (1985) Balloon dilatation of the prostate. Radiology, 157, 57-58.
Reddy PK, Wasserman N, Castenada F, Castenada-Zuniga WR (1987) Trans-urethral balloon dilatation of the prostate for prostatism : preliminary report of non-surgical technique. Journal of Endocrinology, 1, 269-273.
Rousscau H, Puel J, Joffe F (1984) Self-expanding endovascular prosthesis : an experimental study. American Journal of Radiology, 164, 709-714.
Sapozink MD, Boyd SD, Astrahan MA, Jozsef G. Petrovich Z (1990) Trans-urethral hyperthermia for benign prostatic hyperplasia : preliminary clinical results. Journal of Urology, 143, 944-950.
Schulman CC, Zlotta RA (1994) Transurethral needle ablation of the prostate : pathological, radiological and clinical study of a new office procedure for treatment of benign prostatic hyperplasia using low level radiofrequency energy. Seminars in Urology, 3, 205-210.
Servadio C, Leib Z (1984) Hyperthermia in the treatment of prostate cancer. Prostate, 5, 205-211.
Servadio C. Leib Z, Lev A (1986) Further observations on the use or local hyperthermia for the treatment of diseases of theprostate in man. European Urology, 12, 38-40.
Servadio C (1989) Local hyperthermia for the treatment of prostatic disease. In : The Prostate. pp. 223-238. Edited by Fitzpatrick JF and Krane RJ. Edinburgh, Churchill Livingstone.
Siroky MB, Olsson CA, Krane RJ (1979) The flow rate nomogram : I. Development. Journal of Urology, 122, 665-668.
Sterzer F (1980) Microwave apparauls for the treatment of cancer by hyperthermia. Microwave Journal, 23, 39-44.
Storm F, Harrison WH, Elliot R. Morton D (1979) Normal tissue and solid tumour effects of hyperthermia in animal models and clinical trials. Cancer Researdh, 39, 2245-2249.
Strohmaier WL, Bichler K-H, Fluchter SH, Wilbert DM (1990) Local microwave hyperthermia of benign prostatic hyperplasia. Journal of Urology, 144, 913-917.
Sunderman WF (1970) Metal carcinogenesis in experimental animals. Food and Cosmetic Toxicology, 9, 105-120.
Timoney AG, Davies BL, Hibberd RD, Wickham JEA (1991) The use of robots in surgery : the development of a frame for prostatectomy. Journal of Endourology, 5, 165-168.
Vale JA, Mnler PD, Kirby RS (1993) Balloon dilatation of the prostate : should it have a place in the urologist's armamentarium? Journal of the Royal Society of Medicine, 86, 83-86.
Williams DF (1981) Titanium as a metal for implantation. Journal of Medical Engineering and Technology, 1, 195-202.
Wishnow KI, Newman CT, Cromeens DE, Price RE, Eschenbach AC (1990). Safety of transurethral laser treatment of the prostate. Journal of Urology145, 267A.
Yerushalmi A, Servadio C, Leib Z, Fishelovitz Y, Rakowsky A, Stein JA (1982) Local hyperthermia for treatment of carcinoma of the prostate ; a preliminary report. Prostate, 6, 623-630.
Yerushalmi A, Shpirer Z, Hod I, Gottesfeld F, Bass DD (1983) Normal tissue response to localized deep microwave hyperthermia in the rabbit's prostate : a preclinical study. International Journal of Radiation Oncology Biology and Physics, 9, 77-81.
Yerushalmi A, Fisllelowitz Y, Singer D, Reiner I. Areilly J, Abramovici Y, Catsenelson R, Levy E, Shani A (1985) Localized deep microwave hyperthermia n the treatment of poor operative risk patients with benign prostatic hyperplasia. Journal of Urology, 133, 873-876.

第8章 薬剤療法の選択

P.125 掲載の参考文献
Abrams PH, Shah PJR, Stone AR, Choa RG (1982) Bladder outflow obstruction treated with phenoxybenzamine. British Journal of Urology, 54, 527-530.
Abrams P, Schulman C, Vaage S and the European Tamsulosin Study Group (1995) Tamsulosin for symptomatic BPH. British Journal of Urology, 76, 325-336.
Alquist RP (1948) Astudy of the adrenotropic receptors. American Journal of Physiology, 153, 586-600.
Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtoren T, Tveter K and the Scandinavian BPH Study Group (1995) Can finasteride reverse the progress of BPH? A two-year placebo-controlled study. Urology, 46, 631-637.
Anderson KM, Liao S (1968) Selective retention of dihydrotestosterone by prostate nuclei. Nature, 219, 277-279.
Ball AJ. Fenely RCL, Abrams P (1981) The natural history of untreated prostatism. British Journal of Urology, 53, 613-616.
Bartsch G, Frick J, Ruegg I, Bucher M, Holliger O, Oberholzer M, Rohr HP (1979) Electron microscopic stereological analysis of the human prostate and of benign prostatic hyperplasia. Journal of Urology, 122, 481-486.
Berges RR, Windeler J, Trampisch HJ, Sense TH and the Beta-Sitosterol Study Group (1995) Randomized, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet, 345, 1529-1532.
Boreham PF, Braithwaite P, Milewski P, Pearsdn H (1977) Alpha-adrenergic blockers in prostatism. British Journal of Surgery, 64, 756-757.
Bosch RJ, Griffiths DJ, Blom J, Schroeder FH (1989) Treatment of benign prostatic hyperplasia by androgen deprivation : effects on prostate size and urodynamic parameters. Journal of Urology, 141, 68-72.
Boyarsky S, Jones G, Paulson DF, Prout GR (1977) A new look at bladder neck obstruction by the Food and Drug Administration regulators : guidelines for investigation of benign prostatic hypertrophy, Transactions of the American Association of Genitourinary Surgeons, 68, 29-32.
Boyle P, Gould AL, Roehrhom CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride : meta-analysis of randomised clinical trials. Urology, 48, 398-405,
Brawer M, Epstein H, Adams G, Henry D, Clifton G (1992) Efficacy and safety of terazosin in patients with symptoms of benign prostatic hyperplasia : a new double-blind study. Journal of Urology, 147, 365A.
Brooks JR, Baptista EM, Berman C, Ham EA, Hutchins M, Johnson D, Prumka R, Rasmusson GH, Reynolds GF, Schmitt S, Arth GE (1981) Response of rat ventral prostate to a new and novel 5-alpha-reductase inhibitor. Endocrinology, 109, 830-836.
Brooks JR, Berman D, Glitza MS, Gordon LR, Prumka RL, Reynolds GF, Rasmusson GH (1982) Effect of a new 5-alpha-reductase inhibitor on size, histological characteristics and androgen concentrations of the canine prostate. The Prostate, 3, 35-44.
Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5-alpha-adrostan-17-beta-ol-3-one by rate prostate in vitro and in vivo. Journal of Biological Chemistry, 243, 2012-2021.
Buzelin JM, Herbert M, Blondin P and the PRAZALF Group (1993) Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia : a comparative study with prazosin. Bnitish Journal of Urology, 72, 992-997.
Cabot AT (1896) The question of castration for enlarged prostate. Annals of Surgery, 24, 265-309.
Caine M. Perlberg S, Gordon R (1975a) The treatment of benign prostatic hypertrophy with flutamide (SCH 13521) : a placebo controlled study. Journal of Urology, 114, 564-568.
Caine M, Raz S. Zeigler M (1975b) Adrenergic and cholinergic receptors in the human prostate. prostatic capsule and bladder neck. British Journal of Urology, 47, 193-202.
Caine M, Pfau A, Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. British Journal of Urology, 48, 255-259.
Cainc M, Perlberg S (1977) Dynamics of acute retention in prostatic patients and role of adrenergic receptors. Urology, 9, 399-403.
Caine M, Perlberg S, Meretyk S (1978) A placebo controlled trial of the effect of phenoxybenzamine in benign prostatic obstruction. British Journal of Urology, 50, 551-554,
Caine M, Perlberg S, Shapiro A (1980) Phenoxybenzamine for benign prostatic obstruction. Urology, 17, 542-546.
Caine M (1986) The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. Journal of Urology, 136, 1-4.
Caine M (1988) Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology, 32 (Suppl.), 16-20.
Carbin BE, Larsson B, Lindahl O (1990) Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology, 66, 639-641.
Champault G, Patel JC, Bonnard AM (1984) A double-blind trial of an extract of the plant Serenoa repens in benign prostatichyperplasia. British Journal of Clinical Pharmacology, 18, 461-462.
Chapple CR, Christmas TJ, Miiroy EJG (1990) A twelve week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urologia Internationalis, 45, 47-55.
Chapple CR, Carter P, Christmas TJ, Noble JG, Kirby RS,. Abrams P, Milroy EJG (1991) A three month double-blind placebo-controlled trial of doxazosin as a treatment for benign prostatic hyperplasia obstruction. Neurourology and Urodynamics, 10, 298-299.
Chow W, Hahn D, Sandhu D, Slaney P, Henshaw R, Das G, Wells P (1990) Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. British Journal of Urology, 65, 36-38.
Christensen MM, Bendix Hollne J, Rasmussen PC, Jacobsen F, Nielsen J. Norgaard JP, Olesen S, Noer I, Wolf H, Husted SE (1993) Doxazosin treatment in patients with prostatic obstruction. A double-blind, placebo-controlled study. Scandinavian Journal of Urology and Nephrology, 27, 39-44.
Dreikorn K, Richter R (1989) Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. In : Prostatic Hyperplasia, pp. 109-121. Edited by Ackermann R and Scroder FH. Berlin, Walter de Gruyter.
Dunzendorfer U, Jonas D. Weber W (1976) The autonomic innervation of the human prostate. Histochemistry of acetyl-cholinesterase in the normal and pathological state. Urological Research, 4, 29-31.
Dunzendorfer U (1988) Clinical experience : symptomatic management of BPH with terazosin. Urology, 32 (Suppl.). 27-31.
Eri LM, Tveter KJ (1995) Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. Journal of Urology, 154. 923-934.
Fabricius PG, weizert P, Dunzendorfer U, MacHannaford JM, Maurath C (1990) Efficacy of once-a-day terazosin in benign prostatic hyperplasia : a randomized. double-blind, placebo-controlled clinical trial. Prostate. 3, 85-93.
Fair WR, Presti JC, Sogani P, Andriole G, Seidmon J, Fergusson D, Gormley GJ (1991) Multicentre, randomized double-blind placebo-controlled study to investigate the effect of finasteride (MW 906) on stage D prostate cancer. Journal of Urology, 145, 317A.
Farnsworth WE. Brown JR (1963) Testosterone metabolism in the prostate. National Cancer Institute Monographs, 12, 323-325.
Farrar DJ, Pryor JS (1976) The effect of bromocriptine in patients with benign prostatic hypertrophy. British Journal of Urology, 48, 73-75.
Fawzy A, Braun K, Lewis GP, Gaffrey M, Ice K, Dias N (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients : a multicenter study. Journal of Urology, 154, 105-109.
Finasteride Study Group (1993) Finasteride (MK906) in the treatment of benign prostatic hyperplasia. Prostate, 22, 291-299.
Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G (1995) Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. European Journal of Pharmacology, 288, 201-207.
Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y (1982) Alpha-adrenergic tlctivity and urethral pressure in prostatic zone in benign prostatic hypertrophy. Journal of Urology, 128, 836-839.
Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyat MJ, O'Leary MP, Painter MR (1995) Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. Journal of Urology, 154, 205-206.
Geller J, Bora R, Roberts T, Newman H, Lin A. Silva R (1965) The treatment of benign prostatic hypertrophy and hypoxyprogesterone caproate. Effect on clinical symptoms. morphology alld endocrine function. Journal of the American Medical Association, 193, 121-128.
Gilberti C, Damonte P, Michelotti P, Martorana G (1984) The effect of thymoxamine in benign prostatic hypertrophy : a double-blind cross-over study. IRCS Medical Science, 12, 591.
Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffrey M, Ice K, Dias N (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate hypertension : a double-blind, placebo-controlled, dose-response multicentre study. Journal of Urology, 154, 110-115.
Gingell JC, Knonagel H, Kurth KH, Tunn UW (1995) Placebo controued double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. Journal of Urology, 154, 399-401.
Gklyama T, Yachika S, Iguchi M, Kohri K, Kenoka S< Matsuura T, Nagai N, Kurita T (1983) Clinical studies. uroflowmetric and ultrasonography evaluation of oxendolon on benign prostatic hypertrophy. Acta Urologica of Japan, 25, 535-536.
Gormley GJ, Stoner E, Bruskevitz RC and the Finasteride Study Group (1992) The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine, 327, 1185-1191.
Guess HA, Jacobsen SJ, Girman CJ, Oesterling JE, Chute CG, Panser LA, Lieber MM (1995) The role of community-based longitudinal studies in evaluating treatment effects-example : benign prostatic hyperplasia. Medical Care, 33 (4), 26-35.
Hansen BJ, Nordhng J, Mensink HJA (1993) Alfuzosin in the treatment of benign prostatic hyperplasia : effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scandinavian Journal of Urology and Nephrology, 157, 169-176.
Hedlund H, Andersson KE, Ek A (1983) Effect of prazosin in patients with benign prostatic obstruction. Journal of Urology, 130, 275-278.
Hedhlnd H, Andersson KE, Larsson B (1985) Alpha receptors and muscarinic receptors in the isolated human prostate. Journal of Urology, 134, 1291-1298.
Hedlund H, Andersson KE (1988) Effects of prazosin and carbachol in patients with benign prostatic hypertrophy. Scandinavian Journal of Urology and Nephrology, 22, 19-22.
Horby-Petersen J, Schmidt PF, Meyhoff HH, Frimoldt-Moller C, Mathiesen FR (1985) The effects of a new serotonin receptor antagonist (ketanserin) on the lower urinary tract function, in patients with prostatism. Journal of Urotogy, 133, 1095-1098.
Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. Journal of Urology, 43, 705-714.
Iacovou JW, Dunn M (1987) Indoramin-an effective new drug in the management of bladder outflow obstruction. British Journal of Urology, 60, 526-528.
Imperato-McGinley J, Guevro L, Gauteri T and Petersen RE (1974) Steroid 5-alpha-reductase deficiency in man : an inherited form of pseudohermaphroditism. Science, 186, 1213-1215.
Jardin A, Bensadounm H, Delauche-Cavallier MC, Attali P (1991) Alfuzosin f or treatment of benign prostatic hypertrophy. Lancet, 337, 457-461.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P and BPH ALF group (1994) Long term treatment of benign prostatic hyperplasia with alfuzosin : a 24-30 month study. Bnitish Journal of Urology, 74, 579-584.
Jensen D (1981) Uninhibited neurogenic bladder treated with prazosin. Scandinavian Journal Urology and Nephrology, 15, 229-233.
Kaufman J. Goodwin W E (1959) Hormonal management of the benign obstructing prostate : use of combined androgen-oestrdgen therapy. Journal of Urology, 81, 165-171.
Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H (1990) Use of an alpha-1 blocker, YM 617, in the treatment of benign prostatic hypertrophy. Journal of Urology, 144, 908-912.
Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG (1987) Prazosin in the treatment of prostatic obstruction. A placebo controlled study. British Journal of Urology, 60, 136-142.
Kirby RS, Eardley J, Bryan J, Vale JA, Miller PD, Christmas TJ, Liu S (1991) A urodynamic study of a 5-alpha-reductase inhibitor in the treatment of infravesical obstruction due to BPH. Neurology and Urodynamics, 10, 300-301.
Kirby RS, Bryan J, Christmas TJ, Vale J, Eardley I, Webb J (1992) Finasteride in the management of benign prostate hyperplasia-a urodynamic study. Bnitish Journal of Urology, 70, 65-72.
Kirby RS, Vale J, Bryan J, Holmes K, Webb JAW (1993) Long-term urodynamic effects of finasteride in benign prostatic hyperplasia : a pilot study. European Urology, 24, 20-26.
Kirby RS (1995a) Efficacy of doxazosin in nolmotensive and hypertensive patients with benign prostatic hyperplasia. Scandinavian Journal of Urology and Nephrology, 29, 29-33.
Kirby RS (1995b) Doxazosin in benign prostatic hyperplasia : effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology, 46, 182-186.
Kleeman FJ (1970) The physiology of the internal urinary sphincter. Journal of Urology, 104, 549-552.
Krane RJ. Olsson CA (1973) Phenoxybenzamine in neurogenic bladder dysfunction. I. A theory of micturition. Journal of Urology, 110, 650-652.
Langer SZ (1974) Presynaptic regulation of noradrenaline release. Biochemical Pharmacology, 23, 1793-1798.
Lepor H, Shapiro E (1984) Characterization of alpha-1 adrenergic receptors in human benign prostatic hyperplasia. Journal of Urology, 132, 1226-1229.
Lepor H, Gup DL Bauman M, Shapiro E (1988) Laboratory assessment of terazosion and alpha-1blockade in prostatic hyperplasia. Urology, 32 (Suppl.), 21-26.
Lepor H, Knapp-Maloney G, Sunshine H (1990) A dose titration study evaluating terazosin, a selective, once-a-day alpha-1 blocker for the treatment of symptomatic benign prostatic hyperplasia. Journal of Urology, 144, 1393-1397.
Lepor H, Machi G (1992) The relative efficacy of terazosin versus terazosin and flutamide tot the treatment of symptomatic BPH. Prostate, 20, 89-93.
Lepor H, Soloway M, Klilnberg IW, Drago JR, Narayan P, Laddu A, Maurath C (1992) Long term safety and efficacy of terazosin, a selective alpha-1 blocker, in patients with benign prostatic hyperplasia (BPH). Journal of Urology, 147, 365A.
Lepor H d 995) Long-term efficacy and safety ofterazosin in patients with benign prostatic hyperplasia. Urology, 45, 406-413.
Leventhal A, Pfau A (1978) Pharmacologic management of post-operative overdistension of the bladder. Surgery, Gynaecology and Obstetrics, 146, 347-349.
Lukacs B, McCarthy C, Grange JC and the QoL BPH Study Group (1993) Long-term quality of life in patients with benign prostatic hypertrophy : preliminary results of a cohort study of 7093 patients treated with the alpha-1 adrenergic blocker alfuzosin. European Urology, 24, 34-40.
Madsen PO, Dorflinger T, Frimoldt-Moller PC, Jensen KM (1984) Candicidin in treatment of benign prostatic hypertrophy. Journal of Urology, 132, 1235-1238.
Malone PR, Cook A, Edmondson R, Gill MW, Shearer RJ (1988) Prostatectomy : patients' perception and long-term follow-up. British Journal of Urology, 61, 234-238.
Martorana G, Gilberti C, Damonte P, Ciprandi G, Direnzio W, Giuliani L (1984) The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study. IRCS Medical Science, 12, 11-12.
Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler A, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR and the Treatment of Mild Hypertension Study Research Group (1993) Treatment of mild hypertension. Final results. Journal of the American Medical Sssociation, 270, 713-724.
Oesterling JE, Juniewicz PE, Walters JR, Strandberg JD, Steel RE, and Ewing LC (1988) Aromatase inhibition in the dog, Effect on growth, function and pathology of the prostate. Journal of Urology, 139, 832-839.
Peirson EL (1946) A study of the effect of stilboestrol therapy on the size of the benignly enlarged prostate gland. Journal of Urology, 55, 73-78.
Perlberg S, Caine M (1977) Dynamics of acute retention in prostatic patients and role of adrenergic receptors. Urology, 9, 399-403.
Pool JL (1991) Effects of doxazosin on serum lipids : a review of the clinical data and molecular basis for altered lipid metabolism. American Heart Journal, 121, 251-262.
Pool JL (1994) Effects of doxazosin on serum lipids : a review of the clinical data and molecular basis for altered lipid metabolism. Journal of Clinical Practice, 74, 8-12.
Ramsay JWA, Scott GI, Whitfield HN (1985) A double blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outfiow obstruction. British Journal of Urology, 57, 657-659.
Rasmusson GH, Reynolds GF, Utre T, Jobson RB, Prumka RL, Berman C, Brooks JR (1984) Azasteroids as nhibitors of rat prostatic 5-alpha-reductase. Journal of Medical Chemistry, 27, 1690-1701.
Reece-Smith H, Memon A, Smart CJ, Dewbury K (1986) The value of permixion in benign prostatic hypertrophy. British Journal of Urology, 58, 36-40.
Rhodes L, Primika RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B (1993) Comparison of finasteride (Proscar) a 5 alpha-reductase inhibitor with various commercial plant estracts and in vivo and in vitro 5 alpha-reductase inhibitor. Prostate, 22, 43-51.
Ronchi F, Margonato A, Ceccardi R, Rigatti P, Rossini BM (1982) Symptomatic treatment of benign prostatic obstruction with nicergoline : a placebo-controlled clinical study and urodynamic evaluation. Urological Research, 1O, 131-134.
Rossi MA, Carillo SV (1985) Does norepinephrine play a central causative role in the process of cardiac hypertrophy? American Heart Journal, 100, 622-624.
Ruffolo RR, Nichols AJ, Stadel JM, Hieble P (1991) Structure and function of alpha-adrenoceptors. Pharmacologica Reviews, 43, 475-501.
Schulze H, Barrack ER (1987) Immunocytochemical localization of oestrogen receptors in spontaneous and experimentally induced canine BPH. Prostate, 11, 145-162.
Scott WW, Wade JC (1969) Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. Journal of Urology, 101, 81-85.
Shapiro E, Mazouz B, Caine M (1981) The alpha adrenergic effect of prazosin on the human prostate. Urological Research, 9, 17-20.
Siroky MB, Olsson CA, Krane RJ (1979) The flow rate nomogram : I. Development. Journal of Urology, 122, 665-668.
Stenger A, Tarayre JP, Cavilla E, Delhon A, Charveron M, Morre M, Lauressergues H (1982) Etude pharmatologique et biochemique de l'extrait hexanique de Serenoa repens B. Gazette Medical de France, 89, 2041-2048.
Stodt MA, Abrams (1991) Indoramin in the treatment of prostatic bladder outflow obstruction. British Journal of Urology, 67, 499-501.
Stone NN, Fair WR, Fishman J (1986) Oestrogen formation in human prostate tissue from patients with and without BPH. Prostate, 9, 311-318.
Stone N, Cleian S, Ray PS (1989a) A double-blind randomized controlled study of the effect of flutamide on benign prostatic hypertrophy : side effects and hormonal changes. Journal of Urology, 141, 307A.
Stone N, Ray PS, Smith JA (1989b) A double-blind radiological controlled study of the effect of flutamide on benign prostatic hypertrophy-clinical efficacy. Journal of Urology, 141, 240A.
Stoner E (1990) The clinical development of a 5-alpha-reductase inhibitor, finasteride. Journal of Steroid Biochemistr y and Molecular Biology, 37, 375-378.
Stoner E (1992) The clinical effects of a 5-alpha-rductase inhibitor, finasteride, on benign prostatic hyperplasia. Journal of Urology, 147, 1298-1302.
Stoner E and the Finasteride Study Group (1994) Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 43, 284-294.
Sultan C, Terraza A, Devillier C, Cavilla E, Briley M, Loire C, Descomps B (1984) Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasta. Journal of Steroid Biochemistry, 20, 515-519.
Tammela TLJ, Kontturi MJ (1993) Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. Journal of Urology, 149, 342-344.
Teillac P, Delauche-Cavalier MC, Attali P (1992) Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. British Journal of Urology, 70, 58-64.
Tunn UW, Schweikurt HU (1989) Aromatase : inhibitors in the management of benign prostatic hyperplasia. In : New Developments in Biosciences 5. Prostatic Hyperplasia, pp. 139-149. Berlin, WaIter de Gruyter.
Vermeulen A, Giagulli VA, Scheppe P, Buntinx A, Stoner E (1989) Hormonal effects of an orally active 4-azasteroid inhibitor of 5-alpha-reductase in humans. The Prostate, 14, 45-53.
Whitfield HN, Doyle PT, Mayo ME, Poopalasingham N (1976) The effect of adrenergic blocking drugs on outflow resistance. British Journal of Urology, 47, 823-827.
Wolf H, Madsen P (1968) Treatment of benign prostatic hypertrophy with progestational agents : a preliminary report. Journal of Urology, 99, 790-85.
Yazawa H, Honda K (1993). Alpha1-adrenoceptor subtype in the rat prostate is preferentiauy the alpha1A subtype. Japanese Journal of pharmacology, 62, 297-304.

第9章 将来展望

P.132 掲載の参考文献
Ball AJ, Feneley RC, Abrams PH (1981) The natural history of untreated prostatism. British Journal of Urology, 53, 613-616.
Barry MJ (1990) Epidemiology and natural history of BPH. Urological Clinics of North America, 17, 495-507.
Craigen AA, Hinkling JB, Saunders CR, Carpenter RG (1969) Natural history of prostatic obstruction. Journal of Royal College of General Practitioners, 18, 226-232.
Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Handley B (1988) Symptom status and quality of life following prostatectomy. Journal of the American Medical Association, 259, 3018-3022.
Garraway WM, Russell EBAW, Lee RJ, Cillins GN, McKelvie GB, Hehir M, Rogers ACN, Simpson RJ (1993) Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. British Journal of General Practice, 43, 318-321.
Garraway WM, Kirby RS (1994) Benign prostatic hyperplasia : effects on quality of life and impact on treatment decisions. Urology, 44, 629-636.
Guluboff ET, Olsson CA (1994) Urologists on a tightrope : coping with a changing economy. Journal of Urology, 151, 1-3.
Hennigan TW, Franks PJ, Hocken DB, Allen-Mersh TG (1990). Rectal examination in general practice. British Medical Journal, 301, 478-480.
Kirby RS, Fitzpatrick J, Kirby MG, Fitzpatrick A (1994) Shared Care for Prostatic Diseases, pp. 1-80. Oxford, Isis Medical Media.
Kirby RS, Chisholm G, Chapple CR, Hudd C, Swallow M, Shore D (1995) Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia : a survey of attitudes among clinicians. Journal of the Royal Society of Medicine, 88, 284-288.
Marchant N (1995) Diseases of the Prostate, p. 60. London : Office of Health Economics No. 113.
McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, Holtgrewe HL, Lange JL, McClennan BL, Mebust WK, Reilly NJ, Roberts RG, Sachs SA, Wasson JH (1994) Benign Prostatic Hyperplasia : Diagnosis and Treatment. Clinical Practice Guideline, No. 8, pp. 1-225. AHCPR publication No. 940582. Rockville MD, US Department of Health and Human Sciences.
Morris SB, Pogson C, Shearer RJ (1995) Shared care for benign prostatic hyperplasia : a feasibility study. British Journal of Urology, 76, 77-80.

最近チェックした商品履歴

Loading...